PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
Phase 2
Completed
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- First Posted Date
- 2003-08-18
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT00067314
- Locations
- π«π·
Pfizer Investigational Site, Vandoeuvre Les Nancy, France
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
Phase 3
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00026273
- Locations
- π«π·
Hopital Tenon, Paris, France
π¦πΉAllgemeines Krankenhaus der Stadt Wien, Vienna (Wien), Austria
π©πͺUniversitats-Krankenhaus Eppendorf, Hamburg, Germany
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
Phase 3
Completed
- Conditions
- Carcinoma, Renal CellKidney Neoplasms
- Interventions
- First Posted Date
- 2003-07-25
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 626
- Registration Number
- NCT00065468
- Locations
Pfizer Investigational Site
A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died
Phase 4
Completed
- Conditions
- Pancreatitis, Acute Necrotizing
- First Posted Date
- 2003-05-28
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT00061438
- Locations
- π¨π¦
Research Site, Montreal, Quebec, Canada
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson Disease
- First Posted Date
- 2003-04-15
- Last Posted Date
- 2006-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 854
- Registration Number
- NCT00058838
- Locations
- πͺπΈ
Pfizer Investigational Site, Zaragoza, Spain
Treatment With SU11248 in Patients With Neuroendocrine Tumors
- First Posted Date
- 2003-03-24
- Last Posted Date
- 2008-07-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT00056693
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Phase 3
Completed
- Conditions
- Candidiasis
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT00056368
- Locations
- πΊπΈ
Versicor, Inc., King of Prussia, Pennsylvania, United States
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Phase 1
Completed
- Conditions
- Neutropenia
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00056381
- Locations
- πΊπΈ
Versicor, King of Prussia, Pennsylvania, United States
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
Phase 2
Completed
- Conditions
- Kidney Neoplasms
- First Posted Date
- 2003-02-13
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 63
- Registration Number
- NCT00054886
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens
Phase 2
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2003-01-23
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00052117
Β© Copyright 2025. All Rights Reserved by MedPath